Biology subjects

Baugh, A.

Publications and source records attributed to Baugh, A..

3 recordsLinked to original sources

bioRxiv2025

Cancer systems immunology reveals myeloid - T cell interactions and B cell activation mediate response to checkpoint inhibition in metastatic breast cancer

Sensitization of the immune-suppressed tumor microenvironment (TME) of breast cancer by histone deacetylase inhibition shows promise, but the mechanisms of sensitization are unknown. We investigated the TME of breast-to-lung metastases by combining experimental and clinical data with theory. Knowledge-guided subclustering of single-cell RNA-sequencing data and cell circuits analysis identified 39 cell states and salient interactions, of which myeloid, T cell and B cell subpopulations were most affected by treatment. Using functional immunologic assays, we verified that inhibition of the ICAM pathway partially recapitulated treatment effects. Mathematical modeling of tumor-immune dynamics confirmed that tumor reduction required simultaneous modulation of multiple TME interactions. We found evidence that treatment affected anti-tumor antibody production. Analysis of patient biopsies via spatial proteomics corroborated preclinical findings: in responders we observed increased B cell activation, mature tertiary lymphoid structures, and increased CD8+ T cell--macrophage distances with treatment. Overall, this study provides a framework for the discovery of cell-cell interactions that govern responses in complex TMEs. Statement of significanceThis study provides a framework for the discovery of cell-cell interactions that control responses in complex TMEs. We not only identify impactful tumor immunologic interactions that facilitate sensitization of the metastatic TME but also demonstrate how interdisciplinary data integration fuels cancer systems immunology to accelerate discovery of mechanisms of successful immunotherapeutic response in breast cancers and other previously unresponsive solid tumor types.

cancer biology↗

bioRxiv2025

Inference of marker genes of subtle cell state changes via iterative logistic regression

We present iterative logistic regression (iLR) for the identification of small sets of informative marker genes. Differential expression and marker gene selection methods for single-cell RNA sequencing (scRNAseq) data can struggle to identify small sets of informative genes, especially for subtle differences between cell states, as can be induced by disease or treatment. iLR applied logistic regression iteratively with a Pareto front optimization to balance gene set size with classification performance. We benchmark iLR on in silico datasets demonstrating comparable performance to the state-of-the-art at single-cell classification using only a fraction of the genes. We test iLR on its ability to distinguish neuronal cell subtypes in healthy vs. autism spectrum disorder patients and find it achieves high accuracy with small sets of disease-relevant genes. We apply iLR to investigate immunotherapeutic effects in cell types from different tumor microenvironments and find that iLR infers informative genes that translate across organs and even species (mouse-to-human) comparison. We predicted via iLR that entinostat acts in part through the modulation of myeloid cell differentiation routes in the lung microenvironment. Overall, iLR provides means to infer interpretable transcriptional signatures from complex datasets with prognostic or therapeutic potential.

bioinformatics↗

bioRxiv2024

Targeting MDSC-HTR2B to Improve Immune Checkpoint Inhibitors in Breast to Brain Metastasis

Myeloid Derived Suppressor Cells (MDSCs) support breast cancer growth via immune suppression and non-immunological mechanisms. Although 15% of patients with breast cancer will develop brain metastasis, there is scant understanding of MDSCs contribution within the breast-to-brain metastatic microenvironment. Utilizing co-culture models mimicking a tumor-neuron-immune microenvironment and patient tissue arrays, we identified serotonergic receptor, HTR2B, on MDSCs to upregulate pNF-{kappa}B and suppress T cell proliferation, resulting in enhanced tumor growth. In vivo murine models of metastatic and intracranial breast tumors treated with FDA-approved, anti-psychotic HTR2B antagonist, clozapine, combined with immunotherapy anti-PD-1 demonstrated a significant increase in survival and increased T cell infiltration. Collectively, these findings reveal a previously unknown role of MDSC-HTR2B in breast-to-brain metastasis, suggesting a novel and immediate therapeutic approach using neurological drugs to treat patients with metastatic breast cancer.

cancer biology↗